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The objective of this study was to test the hypothesis that serotonin
O-sulphate (5-HT-SO4) could be quantified in human plasma using modern liquid
chromatography–mass spectrometry (LC-MS) method as well as develop and validate
that method. First, a suitable LC-MS method for detection of 5-HT-SO4 in human plasma
samples was developed and validated. Second, a Pilot phase involving four healthy
volunteers was executed, where a basal plasma level of 5-HT-SO4 was measured
for all subjects and for one after the intake of 100mg of a 5-hydroxytryptophan
(5-HTP) -containing food supplement used to promote serotonergic stimulation of the
central nervous system. The basal level of 0.9–2.8 ng/mL of 5-HT-SO4 was observed.
The changes of plasma 5HT-O-SO4 showed 1.2 ng/mL before and 22.6 ng/mL 1h after
stimulation. Finally, nine healthy volunteers were selected for the Study phase, where a
basal plasma level of 5-HT-SO4 was measured before and after the intake of 5-HTP. One
hour after stimulation, six study subjects showed a decrease in 5-HT-SO4 levels while
three subjects showed an increase. The changes of plasma 5HT-O-SO4 from the Study
phase showed an average 5-HT-SO4 level of 19.2 ng/mL before and 15.7 ng/mL 1h after
stimulation indicating ability of method to emphasize quantitative changes. This was the
first study in which naturally occurring 5-HT-SO4 was detected in the samples of human
plasma obtained from healthy volunteers. The method developed herein is specific to
the measurement of 5-HT-SO4, sensitive enough to quantify intra-individual changes in
the samples of plasma and opens up new possibilities to evaluate pathways of serotonin
metabolism by minimally invasive methods. The discovery of novel biomarkers using
such approaches is increasingly required to expedite development of mechanism-based
therapeutics and patient stratification.
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INTRODUCTION
Major depressive disorder (MDD) affects 4–6% of adolescents,
which, when left untreated, subsequently leads to an immediate
high suicide risk, long-term chronicity and a poor psychoso-
cial outcome (Masi et al., 2010). Though effective treatments
for mood and anxiety disorders have been available for more
than 40 years, 30–50% of depressed patients and 25% of patients
with anxiety disorder do not respond sufficiently to first-line
treatment with antidepressants. Because patients with MDD may
not respond to antidepressants for several weeks or longer, a
biomarker that predicts treatment effectiveness after only 1 week
could be clinically useful. Additionally, the discovery of novel
biomarkers using minimally invasive approaches is increasingly
required to expedite drug development in the era of mechanism-
based therapeutics and patient stratification (Masi et al., 2010).
The monoamine deficiency theory posits that the underly-
ing pathophysiological basis of depression is a depletion of the
neurotransmitters serotonin (5-HT), norepinephrine (NE) or
dopamine (DA) in the central nervous system (CNS) (Hasler,
2010). The well-known marker of serotonin metabolism in the
brain is 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal
fluid (CSF), because a correlation between low levels of 5-HIAA
in the CSF and suicidal behavior has been reported (Asellus et al.,
2010). Additionally, the effectiveness of antidepressant treatments
has been evaluated based on the CSF 5-HIAA approach. However,
the use of lumbar puncture is restricted for medical and ethical
reasons. On the other hand, increased plasma levels of 5-HIAA
and 5-HT have been observed in depressed patients and that
plasma 5-HIAA directly correlates with the severity of depres-
sion (Mitani et al., 2006). Thus, the laboratory value of 5-HIAA
as a serotonin metabolism biomarker is defined by the ability to
measure this compound both in CSF and plasma. Nevertheless,
the clinical significance of 5-HIAA in CSF is greater than that
in plasma. From the practical convenience point of view, a
biomarker emphasizing CNS specific 5-HT metabolism that does
not require a spinal puncture would be the most valuable. For
such an important role, the serotonin catabolite 5-HT-SO4, could
be evaluated.
A sulphation reaction of serotonin to its biotransformation
product 5-HT-SO4 was described in the middle of the last cen-
tury (Kishimoto et al., 1961). Animal experiments during later
years revealed that 5-HT-SO4 is the final product of serotonin
catabolism, which is rapidly excreted from the organism (Hidaka
et al., 1969; Rose and Bleszynski, 1971). The same compound was
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also found in human CSF (Tyce et al., 1985). During the 1980 and
1990s, 5-HT-O-SO4 was intensively investigated. In one study,
considerable amounts of acid-hydrolysable conjugates of DA, NE,
and 5-HT were detected in the CSF of normal individuals. The
amounts of conjugated amines were small in comparison to the
amounts of homovanillic acid and 5-HIAA (Tyce et al., 1986).
In the other study performed with CSF from humans and ven-
triculocisternal perfusion of African green monkeys, sulphates of
NE, DA, and 5-HT were also found to be present in the CSF
of laboratory animals and humans. Furthermore, the amount
of sulphated amines in human CSF always greatly exceeds the
amount of free amines. The ratio of 5-HT-O-SO4 in perfusates to
5-HT-O-SO4 in plasma increased after intravenous (i/v) injection
of 5-HT-O-SO4 (300–400μg/kg). The ratio of amine sulphate
in the perfusate to amine sulphate in plasma was greater for
5-HT-O-SO4 than for DA-O-sulphate at 60 and 100min after i/v
injection. Finally, because 5-HT-O-SO4 could not be detected in
the plasma of monkeys or humans under normal conditions, it
was confirmed that the 5-HT-O-SO4 in ventriculocisternal per-
fusates undoubtedly originated in the central nervous system
(Tyce et al., 1985).Failure to detect this compound in plasma
during the trials described above is likely due to the early develop-
ment stage of high-performance liquid chromatography (HPLC)
methods.
In recent years, several studies have been performed onmarine
molluscs to determine 5-HT-O-SO4 levels in their nervous sys-
tems. Indeed, 5-HT-O-SO4 was detected in the somato of the
serotonergic metacerebral cells of Aplysia and Pleurobranchaea
as well as the pedal G cells of Pleurobranchaea. The most intrigu-
ing finding, however, was that the fate of 5-HT in the central
nervous system depends upon its release location (Stuart et al.,
2003, 2004). Unfortunately, the clinical significance of 5-HT-O-
SO4 has thus far been lessened, likely due to its absence in the
peripheral blood circulation and the better-established 5-HIAA
method.
As another potential source of 5-HT-O-SO4 a urine was inves-
tigated. Laboratory test animals have been shown to excrete
appreciable amounts of serotonin-O-sulfate after the adminis-
tration of large doses of serotonin. However, the presence of
this serotonin metabolite in the urine of normal man given
oral loads of serotonin was not detected, but in the urine of
patients with carcinoid tumors it has been quantified by uti-
lizing ion exchange resins (Davis et al., 1966). So, the findings
with urine showed lack of 5-HT-O-SO4 under physiological
circumstances, probably due to insensitiveness of the methods
employed. However, since there is a lack of data related to cir-
cadian rhythm of 5-HT-O-SO4 we decided to concentrate on
another body fluid-plasma as more potent source for the future
investigation.
The latest scientific data have allowed us to hypothesize that
the measurement of 5-HT-O-SO4 in human plasma by modern
LC-MS methods is sensitive enough to detect small amounts of
the compound in human plasma. The aim of our research was
thus to develop an appropriate chromatographic method based
on a minimally invasive approach to measure 5-HT-O-SO4 in
human plasma and to test that method in clinical practice on
healthy volunteers.
MATERIALS AND METHODS
This study was approved by the independent ethics committee
for clinical research of medicines and pharmaceutical products
in Latvia namely “Neatkarı¯ga¯ za¯l¸u un farmaceitisko produktu
kl¯ıniska¯s izpe¯tes e¯tikas komiteja” as well as the board of Latvian
Institute of Organic Synthesis. All human subjects provided
informed consent to participate, and written informed consent
was obtained from all participants.
SUBJECTS
Thirteen healthy volunteers were enrolled in the trial. The char-
acteristics of the subjects are summarized in Table 1.
The eligible age range for subjects in the study was 18–80 years
old. Both genders were also eligible for the study. Participation in
this study was also determined by the following inclusion crite-
ria: subjects in general good health and in whom the use of any
of the study food supplement compounds were not contraindi-
cated; subjects who could communicate with the study personnel
and complied with study requirements; subjects not suffering
from depressive mood disorders; subjects not taking any med-
ication that may increase serotonin levels in the organism; and
Table 1 | Study subjects characteristics.
Study ID Age Gender Remarks
PILOT PHASE
SF 1 42 M
SF0-1 34 F Control group not receiving
5-hydroxytryptophan
SF0-2 36 F Control group not receiving
5-hydroxytryptophan
SF0-3 27 F Control group not receiving
5-hydroxytryptophan
STUDY PHASE
SF-2 64 M
SF-3 54 M
SF-4 43 M
SF-5 29 M
SF-6 20 F
SF-7 42 F
SF-8 28 F
SF-9 46 F
SF-10 57 F
The age is given in years, abbreviation: M, refers to male; F, female. In the Pilot
phase the subject SF 1 and all Study phase subjects underwent the serotonergic
stimulation.
Table 2 | MS/MS parameters of serotonin O-sulfate.
Compound MRM transition Cone voltage, V Collision energy, eV
Serotonin 257 >> 160 20 19
sulfate 240 >> 160 35 17
MRM refers to multiple reaction monitoring.
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female subjects that had not been pregnant or breast-feeding.
The following criteria led to exclusion from the study: subjects
with abnormal screening laboratory results that were considered
clinically significant by the investigator; subjects with diagnosed
depressive mood disorders, history of antidepressant treatment or
severe renal insufficiency; subjects who had participated in a clin-
ical trial in the previous 30 days; subjects with known allergies to
any of the active ingredients or excipients of the study compound;
and subjects not complying with all of the inclusion criteria.
Four volunteers were involved in the Pilot and 9 in the Study
phase.
STUDY PROTOCOL
This study was designed to quantify intra-individual changes of
plasma 5HT-O-SO4 using a cohort of healthy subjects.
Pilot phase
Under fasting conditions, baseline blood samples (0 h) from the
four study subjects were collected in 20mL vacuum tubes. To
define the sensitivity of the method to quantitatively detect intra-
individual changes of the 5-HT-O-SO4 levels, serotonergic stim-
ulation of one of the study subjects was performed. The subject
ingested two capsules of a food supplement containing 100mg
FIGURE 1 | The full mass spectra of 5-HT-SO4, daughter ions and
possible scheme of fragmentation. In the spectra (A) besides
molecular ion [M+H]+ with m/z value of 257 a sodium adduct
[M+Na]+ (m/z 279) and some median intensity cleavage products
(m/z- 240; 218; 195) are seen. The mass spectra (B) of molecular
ion decay is linked to the elimination of ammonium (m/z 240) and
sulphuric acid (m/z 160 the most intensive cleavage ion).
Fragmentation scheme of 5-HT-SO4 is seen at the end of the
picture. The (a) shows cleavage of ammonia (b) sulfuric acid residue
and the corresponding m/z values m/z.
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FIGURE 2 | Chromatograms of 5-HT-SO4 samples and MRM
chromatograms. The (A) shows plasma standard solution (containing
96 ng/mL of 5-HT-SO4) where 1.80min retention time peak is seen;
(B) – in the “pure” plasma 1.8min retention time peak is seen;
(C) – purified water where no 1.79–1.80min peak is observed. (D) shows
MRM chromatogram of analytical solution made of 5% serum albumin.
The signal with a retention time ∼1.8min. is not observed. (E) shows
5% serum albumin solution containing 5-HT-SO4 (10 ng/mL). The signal
with retention time 1.80min, which corresponds to the site analyzed is
observed.
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FIGURE 3 | Calibration lines of 5-HT-SO4 during three different days of
analysis. The concentration of 5-HT-SO4 in the plasma samples is given
prior to treatment. For the Calibration 1 concentration range was
4.4–225.2 ng/mL, for the Calibration 2 and 3 the range was
10.7–225.2 ng/mL.
of 5-HTP, 1 h after which a second blood sample was collected.
All samples were subsequently centrifuged, plasma removed
and placed into a 12 × 75 polypropylene microcentrifuge tubes,
thereafter frozen to a minimum temperature of −24◦C. Ten days
later, detection of 5-HT-O-SO4 was performed using LC-MS
methods.
Study phase
As in the Pilot study, baseline blood samples (0 h) of all study
subjects were collected in 20mL vacuum tubes. In this study,
all of the subjects underwent the serotonergic stimulation pro-
cess to ascertain the sensitivity of the method to quantitatively
detect intra-individual changes of the 5-HT-O-SO4 levels. One
hour after ingesting two capsules of a food supplement contain-
ing 100mg 5-HTP, a second post-stimulation blood sample was
obtained from each subject. All blood samples until analysis were
handled as per Pilot phase. HPLC detection of 5-HT-O-SO4 was
performed on the samples after 20 days. All of the blood sam-
ples were collected according to good clinical practice at a certified
medical institution.
FOOD SUPPLEMENT USED IN THE STUDY
To stimulate the serotonergic system, we choose to use an orally
administered food supplement containing the serotonin precur-
sor 5-HTP.
The 330.5mg capsules containing 50.5mg 5-HTP (as Griffonia
simplicifolia seed extract supplied by Synpharma International
Ltd, UK), 1.25mg pyridoxine hydrochloride and 200mg magne-
sium oxide are legally available on the EU market. The rationale
for using a product with this composition is described as follows.
Pyridoxine (vitamin B6) is a cofactor for l-amino acid decarboxy-
lase, an enzyme that catalyses the decarboxylation of a variety of
aromatic amino acids—it converts 5-HTP to serotonin (Turner
et al., 2006). The magnesium oxide serves as a substitution for
magnesium depletion to mimic the fact that dietary magnesium
Table 3 | The statistical parameters of 5-HT-SO4 calibration lines.
Parameter Value
1. Calibration 2. Calibration 3. Calibration
Concentration range,
ng/mL
4.4–225.2 10.7–225.2 10.7–225.2
Correlation coefficient
squared, R2
1.0 1.0 1.0
Slope, A 0.9 1.3 1.8
Free member, B 7.5 11.8 11.3
Range of free
member (α = 0.05)
5.1–10.4 5.1–19.6 6.0–17.7
Statistical significance
of free member
YES YES YES
The “1. Calibration” refers to the range of 4.4–225.2 ng/mL, “2. Calibration” and
“3. Calibration” to the range of 10.7–225.2 ng/mL performed during three differ-
ent days of analysis. A free member of calibration lines statistically differs from
zero in all the cases.
intake often tends to be lower than recommended (Marier, 1986)
and may play a potential role in depressive disorders (Szewczyk
et al., 2008). The intention of using a combination supplement
was to exclude possible effects of dietary deficiencies leading to
impaired serotonin metabolism. The rationale for 5-HTP dosages
and administration regimen was based on findings that the lowest
average dose used in clinical trials was 100mg, and its max-
imal plasmatic concentration was achieved within 1–2 h after
administration (Turner et al., 2006).
We avoided the use of pure 5-HTP because nausea is a general
side effect often encountered during its administration (Jacobs
et al., 2010). We also decided against the addition of carbidopa,
which is known to prevent peripheral conversion of 5-HTP to
5-HT. As previously reported, the average systemic availability
of oral 5-HTP was approximately 70% (Turner et al., 2006), and
there is no consensus as to whether the addition of carbidopa
increases the efficacy of 5-HTP (Zmilacher et al., 1988).
MATERIALS AND REAGENTS
The 5-HT-O-SO4 was purchased from Chemos GmbH. All
solutions were prepared or purchased as follows: acetoni-
trile (Merck, LiChrosolv), formic acid (Fluka), deionized water
(R > 18M/cm, TOC < 10 ppb) produced by a Millipore-Q
water system (Bedford, MA, USA).
INSTRUMENTATION
Analyses were performed on a liquid chromatography (Acquity) -
mass spectrometer (Waters Quattro Micro) tandem device using
MassLynx 4.1 software for data registration.
A Hydrophilic Interaction Liquid Chromatography (HILIC)
type sorbent on a gradient regime achieved chromatographic
separation of the sample components.
Samples for analyses were prepared by precipitation of plasma
proteins with acetonitrile followed by purification with a solid
phase extraction method using the HybridSPE solid phase pre-
cipitation cartridge.
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FIGURE 4 | The method for signal to noise (S/N) ratio
determination. Chromatogram B shows the “clean” plasma sample
no spiking with 5-HT-SO4. The peak with a retention time 1.8min. is
seen, area- 12.3. Chromatogram A shows the plasma sample spiked
with 26.5 ng/mL of 5-HT-SO4, the peak 1.8min, area- 54.4. The
resultant S/N ratio is 4.4.
Chromatographic and mass spectrometer conditions
The analytical column was aWaters Acquity BEHHILIC (1.7μm,
2.1 × 100mm), with a 5μl injection volume. The mobile phase
consisted of acetonitrile (phase A) and a 0.1% formic acid aque-
ous solution (phase B). The following mobile phase parame-
ters were used for these measurements: gradient—0min; 85%
A, 2.5min; 55% A, 3min; 55% A, 5min 85% A, 4min; and
flow—0.2mL/min.
The mass spectrometer was a Micromass Quattro Micro using
a triple quadrupole mass spectrometer. The metabolite 5-HT-O-
SO4 was ionized in a positive mode. The tandem mass spectrom-
etry (MS/MS) parameters are described in Table 2.
PREPARATION OF CALIBRATION STANDARD SOLUTIONS AND
SAMPLES FOR ANALYSIS
Calibration standards for human studies were prepared by dilu-
tion of a serotonin O-sulphate stock solution in 80% methanol
(C = 93μg/mL) to obtain 6 calibration samples with concentra-
tions ranging from 10 to 225 ng/mL.
For human studies, serotonin O-sulphate was quantified by
the standard addition method. Three aliquots (100μL) of each
plasma sample were spiked with 20μL of serotonin O-sulphate
standard solution of various known concentrations (2 samples)
or 20μL of water. Next, 300μL of 1% formic acid solution in
acetonitrile was added to each plasma sample andmixed. Samples
were centrifuged (10min at 10,000 rpm), and the resulting super-
natant was loaded onto the HybridSPE cartridge. The eluate was
then collected in an HPLC vial, and a 5μL aliquot was injected
into the LC-MS system for analysis.
STATISTICS
Statistical analysis of the study changes of plasma 5HT-O-SO4
was performed using MS Excel 07. The changes of plasma
5HT-O-SO4 from human studies were analyzed using the
5-HT-O-SO4 measurements taken at both baseline (0 h) and
post-stimulation (1 h) points. Data were analyzed through a
paired t-test.
RESULTS
HPLC METHOD DEVELOPMENT
The method for detection of 5-HT-O-SO4 in the human plasma
was validated according to “Draft guideline on validation of
bioanalytical methods” published by the European Medicines
Agency (EMEA, 2009) in terms of specificity, linearity, recovery,
accuracy, and precision.
Specificity of the method
Tandem mass spectrometric analysis (MS/MS) was made in a
positive-ion mode (ESI +). The total ion current full mass range
of 5-HT-SO4 and daughter ions is shown on Figure 1. The
electrospray ionization of 5-HT-SO4 was weak. Thus, for the fur-
ther quantitative analysis a following ion transition was used:
(257 >> 160) + (240 >> 160).
Specificity of the method was assessed visually by comparing
multiple reaction monitoring (MRM) chromatograms of plasma
sample spiked with serotonin O-sulfate, samples of plasma and
purified water. As seen in Figure 2, in the plasma based cali-
bration standard (A) and plasma (B) some 1.79–1.80min reten-
tion time peaks can be observed. The purified water samples
treated similarly do not show such signal (C). This signal might
be induced by native content of serotonin sulphate found in
plasma samples. Conclusion was reached because in the analyt-
ical solution made of 5% serum albumin such signal was not seen
(Figure 2).
For the MRM chromatograms shown on Figure 2D the test
solution of 5% serum albumin (buffered to pH= 7 in a phosphate
buffer) was prepared.
Further the 5% serum albumin (buffered as above) was dis-
solved into 0.9% NaCl solution and 10 ng/mL of 5-HT-SO4
added. The MRM chromatogram is shown on Figure 2E.
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Table 4 | The results of 5-HT-SO4 recovery testing.
Serotonin O-sulfate, ng/mL Recovery ± SD, %
26.8 118.2 ± 5.3
45.5 120.7 ± 7.9
59.9 104.2 ± 4.5
156.0 120.2 ± 6.6
The average recovery, % 115.8
Relative SD, % 6.8
The accuracy of results is little dependent on the amount of serotonin O-sulfate
added.
Table 5 | Intralaboratory precision and reduplication of the method.
Day Medium Relative SD Accuracy, %
reduplication ± SD, % for parallel samples %
Day 1 114.7 ± 8.2 12.0 12
Day 2 104.2 ± 4.5 4.3
Day 3 94.5 ± 5.7 10.1
Each plasma sample contains 59.9 ng/mL of 5-HT-SO4.
The results obtained lead to conclusion that the method devel-
oped is specific to the compound of interest—5-HT-SO4.
The linearity and working range
The linearity of detection was evaluated three times in different
days by analyzing calibration standard solutions of 5-HT-SO4.
In the first analysis, the concentration range was 4.4 to
225.2 ng/mL, 2nd and 3rd analysis,—10.7 to 225.2 ng/mL. The
calibration lines are shown on the Figure 3.
Statistical parameters of the calibration lines are described in
Table 3.
This method resulted in a linear relationship between concen-
tration of the analyte (10–225 ng/mL) and mass spectral signal
of 5-HT-SO4 with a calibration curve correlation coefficient
of >0.98.
The data obtained matches to finding that the peak of 5-HT-
SO4 in the plasma samples was observed. The preparation of
calibration standard solutions for the further human studies were
done using concentration range 10 to 225 ng/mL.
The optimal detection limit of 5-HT-SO4 in the plasma sample
was determined to be 26.5 ng/mL. The signal to noise (S/N) ratio
was determined to be 4.4 as shown on Figure 4.
The both “clean” plasma sample not spiked and the sample
spiked with 26.5 ng/mL of 5-HT-SO4 were used.
Recovery
Four different concentrations of 5-HT-SO4 were used for a recov-
ery testing by adding them to the pure plasma samples. Six
samples for each concentration level were prepared. The results
obtained are described in Table 4.
The HPLC method gave correct 5-HT-SO4 detection results,
which were justified by the average level of recovery of the analyte
at 116 ± 8%.
Table 6 | Concentrations of plasma 5-HT-SO4 obtained from the Pilot
study subjects.
Sample Concentration of serotonin-O-sulfate
Average ng/mL SD ng/mL RSD %
SF 1 (Start) 1.2 ±0.04 3.0
SF 1 1h after 5-HTP ingestion 22.6 ±0.03 0.2
SF0-2 control 1.9 ±0.11 5.9
SF0-3 control 0.9 ±0.09 9.8
SF0-4 control 2.8 ±0.31 11.1
The calculation of average ng/mL and relative standard deviation (RSD) is based
on 3 analyses—no 5-HT-SO4 added, 28 and 54 ng/mL of 5-HT-SO4 added.
The relatively high interval of recovery can be explained due
to the matrix effect, caused by somewhat dirty plasma samples
significantly affecting the analytical signal of the compounds.
Intralaboratory reduplication
Accuracy of the method was tested by the preparation of plasma
samples during three different days, in six parallel samples. The
results described in Table 5.
Intra-laboratory accuracy of the method over a 3-day period
was characterized by a standard deviation of ±12%.
Taking into account above mentioned results the method
was concluded to be a suitable technique for measuring basal
5-HT-SO4 levels in human blood samples as well as quantita-
tive changes. Considering this, we decided to test this method in
a Pilot study involving healthy volunteers.
PILOT STUDY
The purpose of the Pilot study was to apply themethod developed
in the first-in-humans study. The concentrations of basal plasma
5-HT-SO4 for all four subjects were measured. The subject SF1
ingested two capsules of a food supplement containing 100mg
5-HTP. To test the intra-individual sensitivity of the method, a
second blood sample from one subject (SF1) was obtained 1 h
after serotonergic stimulation.
Each plasma sample was analyzed three times—without 5-HT-
SO4 and by addition of 5-HT-SO4 standard in two concentration
levels (28 and 54 ng/mL). The average results for each sample are
described in Table 6.
STUDY PHASE
Our main interest was to ascertain quantitative differences of
basal 5-HT-SO4 levels and intra-individual sensitivity of the
quantitation obtained in the Pilot study on a larger number of
subjects. Thus, after measurement of the basal 5-HT-SO4 levels,
all subjects were exposed to serotonergic stimulation and a second
blood sample was analyzed.
Each plasma sample was analyzed three times as per Pilot
study.
The concentrations of plasma 5-HT-SO4 obtained from the
study subjects are described in Table 7.
In six study subjects, a decrease in 5-HT-SO4 levels was
observed 1 h after 5-HTP ingestion.
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Table 7 | Concentrations of plasma 5-HT-SO4 obtained from the study subjects and data of statistical analysis.
Sample Concentration of Concentration of serotonin-O-sulfate Relative change
serotonin-O-sulfate at baseline 1h after 5-HTP ingestion of concentration
Average, ng/mL SD, ng/mL RSD % Average, ng/mL SD, ng/mL RSD % ng/mL
SF-2 20.6 1.2 5.0 14.9 0.5 3.5 5.6
SF-3 22.7 0.6 2.7 16.4 0.6 3.7 6.4
SF-4 23.6 2.4 10.1 14.9 0.2 1.4 8.6
SF-5 17.0 0.1 0.6 10.1 0.4 4.3 6.8
SF-6 28.1 1.1 3.8 21.9 1.0 4.3 6.2
SF-7 26.1 1.2 4.7 27.3 0.6 2.1 −1.1
SF-8 11.6 0.3 2.9 12.6 0.3 2.3 −1
SF-9 15.0 2.3 15.3 17.6 0.3 1.5 −2.6
SF-10 8.1 0.1 1.1 5.3 0.01 0.2 2.8
Average in the group 19.2 6.8 35.3 15.7 6.4 40.8
T -TEST: PAIRED TWO SAMPLE FOR MEANS
P(T ≤ t) one-tail 0.02 t Critical one-tail 1.9 P(T ≤ t) two-tail 0.03 t Critical two-tail 2.3
The calculation of average ng/mL and RSD is based on 3 analyses—no 5-HT-SO4 added, 28 and 54 ng/mL of 5-HT-SO4 added.
Three subjects, however, showed an increase of 5-HT-SO4 1 h
after 5-HTP ingestion.
Paired Two Sample for Means analysis showed statistically
significant differences between individual measurements.
In summary, we developed a suitable LC-MS method for the
detection of 5-HT-SO4 in human plasma samples based on a
minimally invasive laboratory method.
During the Pilot study, we detected 5-HT-SO4 in the plasma
samples of healthy volunteers for the first time. The Study phase
confirmed the suitability of the method developed for clinical
application by detecting basal 5-HT-SO4 levels in plasma samples
and its ability to emphasize quantitative changes.
DISCUSSION
The significance of our research is that, contrary to earlier
findings, we have measured evidence of naturally occurring
5-HT-SO4 in human plasma. The present finding opens up new
possibilities for monitoring minor 5-HT metabolism pathways
in the peripheral blood stream. Furthermore, 5-HT-SO4 could
potentially be employed as a biomarker of MDD severity and
antidepressant treatment efficacy (Mitani et al., 2006), similarly
to 5-HIAA.
The key limitations of this method in the past include the
lack of knowledge on CNS-specific site of 5-HT-SO4 appear-
ances and the fact that monitoring of this compound was only
possible in the CSF. Thus, 5-HIAA had many more advantages
from a feasibility and convenience standpoint. However, we now
have evidence that serotonin O-sulphate is present in the same
body fluids as other 5-HT metabolites. Moreover, taking into
account conclusions regarding doubtful CNS origin of 5-HT-SO4
(Tyce et al., 1985), we have a potential tool to monitor central
serotonergic metabolism in the peripheral blood stream.
For the justification for the HPLCmethod we employed and its
comparison to other available a following concern was taken into
account. Neurotransmitters can be analyzed by gas chromatog-
raphy (GC) but a derivatization step is necessary. Therefore, LC
or capillary electrophoresis (CE) has been more frequently used,
applying electrochemical fluorescence or UV detection. These
methods often require a derivatization of the analytes or do not
provide enough sensitivity or specificity. Therefore, other detec-
tion modes, such as mass spectrometry, have been used. MS has
recently made a big impact on the determination of this type of
compounds and provides several advantages over conventional
methods, because structural information can be given, and more-
over, better sensitivity and selectivity can be achieved (González
et al., 2011).
Despite other studies related to 5-HT-SO4 research used to
employ CE with laser-induced fluorescence (LIF) technique we
concerned the statement that CE-LIF could not fulfill the expec-
tation of becoming a routinely applied technique in clinical
laboratories or pharmaceutical industry. The limited number of
real applications compared to HPLC methods justifies this. The
reasons are the relatively high cost of instrumentation, the lack
of ready to use applications and the need for careful design of
method development requiring skilled and experienced analyst
(Szöko and Tábi, 2010).
However, several questions raised by our findings need to be
addressed. The first is whether the 5-HT-SO4 found in plasma
indeed has CNS origin. The second is to provide a possible expla-
nation of the elevated or lowered sulphate levels observed in the
present research. Future investigations are needed to explain these
findings.
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